[Enoxaparin dose associated with decreased risk of death in COVID-19]

Area of Science:

• Infectious Diseases
• Pharmacology
• Critical Care Medicine

Background:

• The COVID-19 pandemic, originating in December 2019, has led to significant global mortality.
• Despite extensive research, effective pharmacological treatments for COVID-19 remain elusive.

Purpose of the Study:

• To analyze the clinical characteristics and pharmacological interventions in hospitalized COVID-19 patients.
• To investigate the relationship between specific treatments and patient outcomes, including mortality.

Main Methods:

• An observational study was conducted on 200 patients hospitalized with COVID-19 between March and July 2020.
• Data on patient demographics, comorbidities, pharmacological treatments, and clinical evolution were collected.
• Statistical analyses, including univariate, bivariate, and multivariate approaches, were employed.

Main Results:

• The study population comprised 60% males, with 83% having at least one comorbidity; overall mortality was 56%.
• Enoxaparin use, particularly a 60 mg dose, was associated with a reduced risk of death compared to a 40 mg dose.
• Hydroxychloroquine, methylprednisolone, moxifloxacin, and age over 60 were linked to an increased risk of mortality.

Conclusions:

• Hospitalized COVID-19 patients experienced high mortality rates.
• A 60 mg dose of enoxaparin demonstrated a potential survival benefit in this patient cohort.